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A B S T R A C T
Herein we present a female patient aged 61 with Philadelphia negative acute lymphoblastic leukaemia de-
monstrating near haploid karyotype and abnormal TP53 expression at diagnosis, who relapsed with lineage
switch as Acute Monocytic Leukemia post allogeneic stem cell transplantation. Molecular analysis established
that both neoplasms were derived from the same founder clone. The leukemic lineage switch phenomenon has
recently re-attracted interest as mechanism of leukemic evasion post treatment with chimeric antigen receptor T-
cells but there is paucity of data on its presence post allograft or following novel antibody treatments such as
Inotuzumab Ozogamicin or Blinatumomab. Our proposition for cancer research is that near haploidy in ALL
could be linked to leukemic stem cell plasticity evading stem cell transplantation and other immunotherapy
approaches.
Acute leukemia consists of heterogeneous group of clonal malig-
nancies classified by their cell lineage as lymphoid (ALL), myeloid
(AML, or mixed phenotype (MPAL). Each subtype has distinct mole-
cular and genetic alterations associated with it that have significant
prognostic implications and are used to inform management decisions.
Rare cases of lineage switching have been described during the disease
course [1–4] and are typically associated with a poor prognosis. The
precise mechanism behind this phenomenon remains unclear; however,
studies have suggested that lineage commitment of plastic hemato-
poietic progenitors may be multidirectional and reversible upon spe-
cific signals provided by intrinsic and environmental cues [5]. More
recently, lineage switching has been described as a mechanism of chi-
meric antigen receptor (CAR) T-cell therapy resistance. Genomic ana-
lysis and gene editing techniques have enabled us to establish that this
occurs as a result of global reprogramming of ALL with inherent lineage
plasticity. We describe a unique case of relapsed leukaemia with lineage
switch from lymphoid to myeloid three months post allogeneic stem
cell transplant.
Patient X, a 61 year old female, with a background of hypothyr-
oidism, lichen planus, vitiligo, spinal canal stenosis (operated in May
2018) and hypertension, was diagnosed with Philadelphia negative B-
acute lymphoblastic leukaemia in December 2018 (CD34+/19+/
22+/79a+/10weakly+/20+/Lysozyme-/P53+). The leukemic blasts
were small cells with only minimally polymorphic nuclei and very scant
faintly cytoplasm albeit sporadic large blasts with vacuolated cytoplasm
were seen (Figure 2 in Supplement). Cytogenetics demonstrated an
abnormal karyotype with a doubled-up near haploid clone (54, XX, +X,
+X, +6, +6, +11, +11, der(11;21)(p10;q10)x2, +22, +22 [8]/
46,XX [2]. She was treated on the UKALL 14 protocol (registration arm)
and completed phase 1 on 31st January 2019, achieving flow negative
MRD. This was complicated by raised bilirubin attributed to Pegylated
Asparaginase induced hepatic toxicity (her bilirubin increased to
180 mmol/l after a single dose). She went on to receive Phase 2 in-
duction which she completed on 5th April 2019. This was complicated
by intrathecal methotrexate-induced confusion and weakness. She
subsequently received CNS intensification with intravenous
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Methotrexate.
Unfortunately, the bone marrow biopsy post CNS intensification
demonstrated early disease relapse with a moderate to heavy disease
burden of at least 50% of the cellular material being lymphoid blasts.
The phenotype was noted to have changed slightly with loss of ex-
pression of CD20, CD79a and CD10 from the previous specimen. She
commenced salvage chemotherapy with Inotuzumab Ozogamycin (InO)
on 27th June 2019 and achieved MRD negativity post cycle 2. She re-
ceived further cycle of InO along with 2 doses of prophylactic in-
trathecal Cytarabine.
She went on to receive a Fludarabine, Melphalan 100 mg/m2,
Alemtuzumab 30mg- conditioned matched unrelated donor allograft on
20th September 2019 (day 0). To reduce mucositis and hepatic toxi-
cities the melphalan was reduced to 100 mg/m2 and the Alemtuzumab
was reduced to 30 mg in order to boost the graft versus leukaemia ef-
fect. Graft versus host disease (GvHD) prophylaxis also incorporated
Cyclosporine and Mycophenolate Mofetil. Early transplant stay was
uneventful- a mild increase in liver enzymes resolved after
Posaconazole prophylaxis was paused for a few days whilst liver USS
was normal. She achieved neutrophil engraftment on day +16 and was
discharged home on day +18 clinically well. Day +28 chimerism was
100% whole blood and T-cells and in the absence of GvHD the
Mycophenolate Mofetil and Ciclosporin were suspended on day +60
and +75 respectively.
On the 10th December 2019 patient X underwent her day +100
bone marrow assessment and was admitted to hospital with high fevers,
thrombocytopenia, vomiting and deranged LFTs. Abdominal ultrasound
demonstrated hepatomegaly and the MRCP on 17th December found
multiple liver lesions but no biliary duct pathology. She succumbed to
rapid liver failure with associated with pancytopenia, multi-organ
failure, sepsis and Disseminated Intravascular Coagulation (DIC) on
19th of December 2019. The bone marrow results were exceptional:
Morphology demonstrated a 45% infiltrate of abnormal cells with va-
cuolated cytoplasm. The flow cytometry demonstrated monocytic AML
with blast immunophenotype: (CD56+/CD15+/HLADR+/CD64+/
cMPO+/CD11b-/CD13-/CD61/-CD2-/CD11c-/CD14-/CD19-/CD10-/
CD32-). The biopsy also advocated the heavy infiltrate of acute leu-
kaemia differed markedly from the disease seen prior to transplant in
terms of morphology (see Fig. 1) and also immunohistochemistry. Blasts
post-transplant were much larger with much more abundant cytoplasm
and more irregular nuclei comprising acute myeloid leukaemia with
strong P53 expression on immunohistochemistry (CD34-/TdT-/
CD15+/Lysozyme strongly +/P53 strongly +/Ki-67 100%).
Cytogenetic analysis corroborated re-emergence of initial abnormal
clone with masked near-haploidy and gain of two copies of BCR, similar
to that seen at presentation, whilst the molecular measurable residual
disease assessment (MRD) confirmed the presence of founder ALL leu-
kemic clone (3.1 × 10−1 to the level seen in diagnosis). In retrospect,
re-analysis of the bone marrow at diagnosis in terms of flow cytometry
(December 2018) revealed 1.7% CD56+ cells in the blast region with
very low level CD13 and were CD34+ whilst myeloid blasts on relapse
lacked CD34 expression. Question remains over whether these cells
represented the sporadic large vacuolated cells seen in the diagnostic
slide, and whether they were linked to the AML diagnosis post-trans-
plant which also expressed CD56 in a proportion of the cells. In con-
clusion, we deduced leukemic relapse with phenotypic switch rather
than de novo, or therapy-related AML.
Lineage conversion of acute leukaemia has been reported rarely in
the literature (see Table 1) [6], supporting the existence of stem cell
plasticity with a common pathway for B-cell and myeloid progenitors.
The fact that lineage switching appears to be more common with spe-
cific genetic subtypes of leukaemia, including those with MLL gene
rearrangements, which may have a more inherent plasticity, further
supports this notion.
The presented case is unique for two reasons: i) It is the first time
that the lineage switch phenomenon has been described in Philadelphia
Negative ALL with near haploidy and TP53 mutations [7], and ii)
Leukemic Lineage switch has been presumably driven by strong im-
munological pressure exerted by the graft versus leukemia effect as well
salvage with InO. Lineage switch leukemia in patients treated on che-
motherapy stems from either clonal selection or genomic editing that
reinforces lineage reprogramming. The leukemic switch in this patient
might be explained on the basis of second mechanism because the flow
cytometry repeat analysis and the bone marrow biopsy did not show
convincing evidence of bi-lineage or bi-phenotypic leukemia at diag-
nosis with consequent clonal selection. This is in line with Jakoby et al.
who demonstrated in a series of experiments that relapsing myeloid
clones were not detectable prior to CD19 CART administration [4].
Lineage switching in leukemias is more frequent in children than in
adults and most cases are ALL converting to AML. Lineage switch me-
chanisms remain to be elucidated but they might be operating at dif-
ferent levels: i) individual cellular level defined by transcription and
epigenetic factors; and ii) at the cell/environmental interaction wherein
stem cell reprogramming takes place in response to immune and other
extrinsic stress factors [7]. The latter argument is supported by the
observation that late relapses to CD19 CART cell treatment can occur as
lineage switch AML and this is rather mediated by abrogated expression
of the B-cell transcription factors resulting in complete loss of B-cell
differentiation pathways. Similar process of plasticity-driven following
CD19-directed immunotherapy has been described in CLL with Richter
transformation into a plasmablastic lymphoma and in two patients with
MLL rearranged ALL transformed to AML and following Blinatumomab
treatment [8,9]. Intrinsic factors precipitating the switch to AML in the
present case were probably correlated with near haploid chromosomal
status. Near haploidy (24–30 chromosomes) has only been once re-
ported in adult ALL and confers very poor prognosis [10]. It is often
Fig. 1. Upper Panel: Bone marrow biopsy in May 2019 illustrating ALL relapse
pre-transplant in June 2019. Lower Panel: Bone marrow biopsy revealing
monocytic AML post-transplant in December 2019.
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associated with aberrant TP53 expression and consistently with our
report, hypodiploid ALL is sometimes characterised by blast cells of two
different sizes wherein the smaller blasts display near haploidy and the
larger are hyperdiploid via endo-reduplication (replication of the
chromosomes without subsequent cytoplasm division). Near-haploid
ALL bears mutations targeting receptor tyrosine kinase and RAS sig-
naling (mainly NF), histone modifiers (CREBBP), cell cycle genes
CDKN2A/B, the6p22 histone gene cluster, and B-cell differentiation
factors IKZF3, and PAG1 [11]. Taking all this together, we could
speculate that the lineage switch to monocytic AML in this case was
driven by stochastic constellation of mutations perturbing the cell cycle,
DNA repair and epigenetic differentiation pathways under immune
selection exerted by the graft immune cells and InO treatment. Notably,
our patient exhibited overwhelming leukemic infiltration of the liver
with sudden liver failure and it is to be hypothesised the inciting
transforming event to AML might have taken place extramedullary, in
the liver, where the graft versus leukemia surveillance is less potent.
To summarize, we reflected on the (first to be reported) case of an
adult near haploid ALL patient who relapsed as monocytic AML post
allograft. The present study opens questions for research with regards to
the nature of leukemic stem cell as well as transdifferentiating and
clonal selection pathways in hematological malignancies.
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Table 1
Reported cases of phenotypic switch in acute leukaemia.
Study Circumstances of switch
Stass 1984 5 patients with ALL at diagnosis converted to AML and 1 from AML to ALL
All patients had received lineage-specific multi-agent chemotherapy and achieved a complete remission prior to lineage switch
3 patients from ALL to FAB M1,, 1 patient to FAB M4 and 1 patient unclassifiable
1 patient converted from AML to T-ALL
Shendi 1995 13 -year old girl with B-ALL relapsed with AML FAB M2 1-year post cessation of treatment
Lounici 2000 46-year old female with AML FAB M4 relapsed with BCP-ALL 6 months post autologous transplant for AML
Rossi 2012 9 cases of lineage switch in childhood acute leukaemia
7 from lymphoid to myeloid, 2 from myeloid to lymphoid
4 patients pro B-ALL to AML M5, 2 patients switched from pre B-ALL (1 to AML M4 and 1 to M5), 1 from common ALL to AML M5 and 2 patients switched from
AML M5 to pro B-ALL- in both these cases the B cell precursor lymphoblasts already co-existed at the moment of diagnosis as a minor population (25% and 4%
respectively) with the predominant myeloblasts and should therefore be considered as bilineal leukaemias
Translocations with involvement of the 11q23 region or mixed lineage leukaemia (MLL) gene were detected in 7 of the 9 of these cases, all of them infants, and the
other 2 cases had unspecific abnormalities of chromosome 6 in 1 case and chromosome 19 in the other. All patients reported in this case series died- 2 for sepsis
and CNS bleeding during induction, 5 of progressive disease, , 1 patient died in complete remission due to sepsis and another patient died of relapse
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